Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

GoodRx Erupts 35% on Mixed Results but Analysts Praise Better Visibility

Published 08/09/2022, 08:20 PM
© Reuters
KR
-
GDRX
-

By Senad Karaahmetovic

Shares of GoodRx (NASDAQ:GDRX) are up about 35% in premarket trading Tuesday after the company reported decent Q2 results and resolved the dispute between its pharmacy benefit management customers and Kroger.

The telemedicine company reported Q2 adjusted EPS of 6c, down from 8c in the year-ago period, and above the analyst consensus of 4c per share. GDRX reported second-quarter revenue of $191.8 million, up 8.6% YoY and topping the consensus projection of $184.9 million.

Adjusted EBITDA stood at $47.2 million in the quarter, down 14% YoY, but beating the consensus estimates of $34.8 million.

For Q3, GDRX expects revenue of around $185 million, missing the estimates of $200.8 million. It also expects a Q3 adjusted EBITDA of roughly 20%.

While GoodRx said it resolved its issue with the grocer Kroger (NYSE:KR), the company will not be providing FY guidance as the exact impact of the dispute remains unclear.

An analyst from Morgan Stanley is positive about Kroger developments as it removes an overhang in the stock.

“Pharmacies may have more power/influence on consumer behavior than perceived, which ultimately could lead to additional price erosion over time. Moreover, excluding a $35-40mn drag expected from Kroger in 3Q, guidance implies y/y prescription transaction revenue growth is expected to be only +5%, raising questions on core growth and funnel conversion,” the analyst added in a note.

A Goldman Sachs analyst remains Neutral-rated amid limited visibility into forward trends.

“We expect a return to more normalized growth and elements of margin structure as likely to remain top of investor focus looking beyond Q3 commentary into Q4 and the next year. Longer term, we still see GoodRx as an emerging multi-sided and multi-product platform that is delivering savings & conveniences to consumers and volumes to its industry partners in a fragmented end market (US healthcare) while also producing a rare mix of high growth and strong margins over our 5 year forecast period,” the analyst said.

 

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.